MedPath

Efficacy of hepatitis A vaccination in immunocompromised travelers.

Conditions
hepatits AvaccinationimmunosuppressionHepatitis Avaccinatieimmuunsuppressie
Registration Number
NL-OMON26720
Lead Sponsor
no sponsorfund=initiator=sponsor
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
600
Inclusion Criteria

1. All consecutive patients > 18 years of age using immunosuppressive medication who come to the travel clinics and need vaccination with hepatitis A according to LCR guidelines.

- Immunosuppressive medication is defined as use of cyclosporine A, azathioprine, cyclophosphamide, methotrexate, TNF-á blockers, prednisone use eqal to 10 mg/day or a cumulative dose of > 700 mg., tacrolimus, mycophenolate mofetil.

Exclusion Criteria

1. Allergy to the advised vaccine or its components.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Antibody titres after booster vaccination.
Secondary Outcome Measures
NameTimeMethod
- Antibody titres after first hepatitis A vaccination<br /><br>- Antibody production after the booster vaccination for hepatitis A<br /><br>- Determination of disease or medication related and demographic parameters that are predictive for decreased antibody production to hepatitis A vaccination.
© Copyright 2025. All Rights Reserved by MedPath